Emerald Mutual Fund Advisers Trust increased its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 250.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,556,745 shares of the medical research company’s stock after acquiring an additional 1,112,939 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in NeoGenomics were worth $23,896,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the stock. Jennison Associates LLC increased its holdings in NeoGenomics by 18.7% during the 2nd quarter. Jennison Associates LLC now owns 43,736 shares of the medical research company’s stock worth $573,000 after purchasing an additional 6,888 shares in the last quarter. Cornerstone Wealth Management LLC bought a new position in NeoGenomics during the 2nd quarter worth about $528,000. Howland Capital Management LLC increased its holdings in NeoGenomics by 39.8% during the 3rd quarter. Howland Capital Management LLC now owns 30,449 shares of the medical research company’s stock worth $467,000 after purchasing an additional 8,667 shares in the last quarter. Sei Investments Co. increased its holdings in NeoGenomics by 18.4% during the 2nd quarter. Sei Investments Co. now owns 58,141 shares of the medical research company’s stock worth $762,000 after purchasing an additional 9,026 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in NeoGenomics by 0.3% during the 1st quarter. BlackRock Inc. now owns 3,964,943 shares of the medical research company’s stock worth $32,354,000 after purchasing an additional 12,147 shares in the last quarter. 81.54% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have issued reports on NEO. BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a report on Saturday. First Analysis set a $16.00 target price on NeoGenomics and gave the stock a “buy” rating in a report on Tuesday, September 18th. Leerink Swann began coverage on NeoGenomics in a report on Tuesday, August 21st. They issued an “outperform” rating and a $18.00 price objective for the company. Finally, Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a report on Thursday, July 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. NeoGenomics presently has a consensus rating of “Buy” and a consensus target price of $19.25.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported $0.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.03. The company had revenue of $69.10 million during the quarter, compared to analysts’ expectations of $66.13 million. NeoGenomics had a negative return on equity of 0.36% and a negative net margin of 0.98%. NeoGenomics’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.01 EPS. As a group, sell-side analysts forecast that NeoGenomics, Inc. will post 0.08 EPS for the current fiscal year.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Featured Story: Hedge Funds – How They Work For Investors
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.